Unbiased Analysis of Today's Healthcare Issues

Why “value” is central to true health care reform

Morning Consult has an interesting piece from Mark Linthicum, the Director of Scientific Communication at the Innovation and Value Initiative (IVI) titled “Why Understanding Value Is Central to True Health Care Reform“.  In the piece he argues: The true problem is that dollars are poured into a system without any clear understanding of how worthwhile […]

Read the rest of this entry »

Understanding The Value Of Innovations In Medicine

Today, there was an excellent briefing put on by Health Affairs at the National Press Club. The topic was “Understanding the Value of Innovations in Medicine” and the briefing contained two panel discussions (see agenda).  The first panel , “Many Stakeholders, Many Values: Measuring Value In A Diverse Healthcare” featured expert economists, epidemiologists, and patient […]

Read the rest of this entry »

Does value vary by stakeholder perspective?

According to Innovation and Value Initiative Executive Director Darius Lakdawalla, the answer is yes.  Here is his interview response on AJMCtv.

Read the rest of this entry »

Do the US and UK health care systems have anything in common?

The United Kingdom’s National Health Services provides universal health coverage at not cost to patients.  On the other hand, in the U.S. not all people have insurance, and further insurance can be provided by public entities (e.g., Medicare, Medicaid), private and employer-provided health insurance, and other sources.  Whereas the NHS system is highly centralized, the U.S. […]

Read the rest of this entry »

The Case For Patient-Centered Assessment Of Value

Value assessments are all the rage these days. From ASCO to ESMO, from MSKCC to AHA/ACC, from AMCP to ICER, there are a variety of value frameworks (and acronyms) out there. In the Health Affairs blog today, Alan Balch and Darius Lakdawalla make the case that treatment value should be measured from a patient-centered approach. […]

Read the rest of this entry »

Applying Cost Effectiveness Analysis to all Health Care Interventions

That is the topic of a Health Affairs blog post published today by James Baumgarder and Peter Neumann.  An excerpt is below. Cost-effectiveness analysis (CEA) is an important tool for assessing and pointing the way toward better health care efficiency. The number of published CEAs on health care interventions has blossomed, averaging 34 per year […]

Read the rest of this entry »

The Price of Everything and the Value of Nothing

That is the title of an article in Eye for Pharma which interviews me about measuring value in health care.  The article highlights a number of issues related to value measurement, health policy and the healthcare marketplace. The article also describes the launch of the Innovation and Value Initiative, a broad coalition of providers, payers, patient advocates, […]

Read the rest of this entry »

Figuring out how to measure value

Unlike some other organizations, [the Innovation and Value Initiative (IVI)] is not interested in a top-down, bureaucratic process for setting prices or measuring value, says Shafrin. Rather, IVI aims to disseminate best practices for measuring value and reimbursing treatments based on this value. “We are looking at balancing innovation and value,” he says. “Some people are […]

Read the rest of this entry »

Assessing Healthcare Value: The Need for a Decentralized And Scientific Approach

Tomas Philipson has an interesting post in Forbes describe how value should be incorporated into the U.S. healthcare system but should be done in way suited for the American market. The American healthcare system is at a crossroads. Shifting to a system that reimburses based on value, rather than volume, of care requires changes in how we […]

Read the rest of this entry »

The AMA on value-based drug pricing

The American Medical Association released a statement yesterday in support of value-based pricing of pharmaceuticals.  However, AMA claims that value-based pricing should follow the following core principles. Value-based prices of pharmaceuticals should be determined by objective, independent entities. They also should be evidence-based and the result of valid and reliable inputs and data that incorporate […]

Read the rest of this entry »